Mezzion Pharma Co.Ltd (140410) - Cash Flow Conversion Efficiency

Latest as of March 2026: -0.391x

Based on the latest financial reports, Mezzion Pharma Co.Ltd (140410) has a cash flow conversion efficiency ratio of -0.391x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-6.07 Billion ≈ $-4.11 Million USD) by net assets (₩15.51 Billion ≈ $10.51 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See debt-free asset ratio of Mezzion Pharma Co.Ltd to measure how much of total assets are equity-financed.

Mezzion Pharma Co.Ltd - Cash Flow Conversion Efficiency Trend (2012–2025)

This chart illustrates how Mezzion Pharma Co.Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check 140410 cash to earnings ratio to evaluate the quality of earnings relative to operating cash generation.

Mezzion Pharma Co.Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Mezzion Pharma Co.Ltd ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Hangzhou Landscape Architecture Design Institute Co Ltd SHE:300649	0.012x
Bosch Fren Sistemleri Sanayi ve Ticaret AS IS:BFREN	0.175x
Shanthi Gears Limited NSE:SHANTIGEAR	0.116x
Cheng Mei Materials Technology Corp TW:4960	0.050x
ALPHA KLSE:0303	0.054x
Bsm Chemical Co Ltd SHE:300796	0.056x
Moso Power Supply Technology Co Ltd SHE:002660	0.069x
Stillfront Group AB (publ) ST:SF	0.040x

Annual Cash Flow Conversion Efficiency for Mezzion Pharma Co.Ltd (2012–2025)

The table below shows the annual cash flow conversion efficiency of Mezzion Pharma Co.Ltd from 2012 to 2025. For the full company profile with market capitalisation and key ratios, see Mezzion Pharma Co.Ltd market cap and net worth.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	₩17.19 Billion ≈ $11.65 Million	₩-16.59 Billion ≈ $-11.24 Million	-0.965x	-140.34%
2024-12-31	₩46.06 Billion ≈ $31.22 Million	₩-18.49 Billion ≈ $-12.53 Million	-0.401x	-123.74%
2023-12-31	₩61.44 Billion ≈ $41.64 Million	₩-11.02 Billion ≈ $-7.47 Million	-0.179x	+61.01%
2022-12-31	₩26.24 Billion ≈ $17.78 Million	₩-12.07 Billion ≈ $-8.18 Million	-0.460x	-91.72%
2021-12-31	₩62.79 Billion ≈ $42.55 Million	₩-15.07 Billion ≈ $-10.21 Million	-0.240x	-84.84%
2020-12-31	₩56.81 Billion ≈ $38.50 Million	₩-7.38 Billion ≈ $-5.00 Million	-0.130x	+73.36%
2019-12-31	₩42.83 Billion ≈ $29.03 Million	₩-20.88 Billion ≈ $-14.15 Million	-0.488x	-28.63%
2018-12-31	₩57.32 Billion ≈ $38.84 Million	₩-21.72 Billion ≈ $-14.72 Million	-0.379x	-52.50%
2017-12-31	₩53.17 Billion ≈ $36.03 Million	₩-13.21 Billion ≈ $-8.95 Million	-0.249x	-115.96%
2016-12-31	₩52.81 Billion ≈ $35.79 Million	₩-6.08 Billion ≈ $-4.12 Million	-0.115x	-506.08%
2015-12-31	₩62.54 Billion ≈ $42.38 Million	₩1.77 Billion ≈ $1.20 Million	0.028x	-42.77%
2012-12-31	₩63.34 Billion ≈ $42.92 Million	₩3.14 Billion ≈ $2.13 Million	0.050x	--

About Mezzion Pharma Co.Ltd

KQ:140410 Korea Pharmaceuticals

Market Cap

$341.71 Million

₩504.23 Billion KRW

Market Cap Rank

#14053 Global

#411 in Korea

Share Price

₩59000.00

Change (1 day)

+15.69%

52-Week Range

₩36450.00 - ₩172700.00

All Time High

₩172700.00